Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim about ENTRESTO fetal toxicity and the specific outcomes associated with second/third trimester exposure and oligohydramnios is fully supported by the provided FDA label excerpts (Sections 5.1 and 8.1).
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered to a pregnant woman.
Supported by the provided label text in 5.1 Fetal Toxicity and 8.1 Pregnancy—Risk Summary.
Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Supported by provided label text in 5.1 Fetal Toxicity and 8.1 Pregnancy—Risk Summary.
Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters can result in reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations including skull hypoplasia, hypotension, and death.
Supported by provided label text in 8.1 Pregnancy—Clinical Considerations (Fetal/Neonatal Adverse Reactions).
Unsupported Statements
Contradictions
Important Omissions
The AI claim did not mention the label’s management guidance upon pregnancy detection (consider alternative drug treatment and discontinue ENTRESTO; advise pregnant woman of potential fetal risk if no alternative and therapy considered lifesaving).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are descriptive of labeled fetal toxicity outcomes and do not introduce dosage, monitoring, or treatment instructions beyond what is omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted pregnancy-discontinuation/alternative-treatment counseling language from the label.
Suggested Improvement
Include the label’s instruction: when pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO; if no appropriate alternative and therapy is lifesaving, advise the patient of potential fetal risk.